SpyGlass Pharma, Inc. Common Stock (SGP) Stock
Fundamentals
Technicals
Analyst Ratings
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 1 articles
published over the past 14 days
About SpyGlass Pharma, Inc. Common Stock
The company is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company seeks to improve patient outcomes by developing durable drug delivery solutions that support long-term disease control and vision preservation, providing confidence for both patients and surgeons. Its lead product candidate, the Bimatoprost Drug Pad–Intraocular Lens System (BIM-IOL System), consists of novel, proprietary drug pads attached to an intraocular lens (IOL) and is designed for implantation during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Malik Y. Kahook M.D. | Co-Founder, President, Chief Medical Officer & Executive Chairman | 1975 |
| Mr. Patrick H. Mooney | CEO & Director | 1974 |
| Dr. Chetan Pujara Ph.D. | Chief Research & Development Officer | 1970 |
| Mr. Glenn Sussman | Co-founder & Chief Technology Advisor | 1964 |
| Dr. Jean-Frederic Viret Ph.D. | Chief Financial Officer | 1966 |
| Mr. James Robert Dennewill Jr. | Chief Operating Officer | 1981 |
| Ms. Shannon Trevino J.D. | General Counsel | — |
| Mr. Mike Pinder | Vice President of Marketing | — |
| Ms. Rachel Gilette | Vice President of Human Resources | — |
| Mr. Paul Yoo O.D. | Senior Vice President of Clinical Development | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
1 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +6.1 | -3.1 | -6.1 | -19.7 | +21.5 | +15.7 | +15.1 | +0.8 |




